Targeted Therapy Stocks List

Recent Signals

Date Stock Signal Type
2021-04-09 APTO 200 DMA Support Bullish
2021-04-09 APTO Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-04-09 APTO MACD Bearish Signal Line Cross Bearish
2021-04-09 APTO 1,2,3 Pullback Bullish Bullish Swing Setup
2021-04-09 AYLA Narrow Range Bar Range Contraction
2021-04-09 BCAB NR7 Range Contraction
2021-04-09 BCAB Narrow Range Bar Range Contraction
2021-04-09 CALA MACD Bearish Signal Line Cross Bearish
2021-04-09 CALA New 52 Week Closing Low Bearish
2021-04-09 CALA NR7 Range Contraction
2021-04-09 CALA Narrow Range Bar Range Contraction
2021-04-09 CALA Stochastic Reached Oversold Weakness
2021-04-09 CELC Doji - Bearish? Reversal
2021-04-09 CELC Crossed Above 20 DMA Bullish
2021-04-09 CELC Crossed Above 50 DMA Bullish
2021-04-09 CELC New 52 Week High Strength
2021-04-09 CELC Volume Surge Other
2021-04-09 CELC Wide Range Bar Range Expansion
2021-04-09 CELC New 52 Week Closing High Bullish
2021-04-09 CELC Gilligan's Island Sell Setup Bearish Swing Setup
2021-04-09 CELC Expansion Breakout Bullish Swing Setup
2021-04-09 CELC MACD Bullish Centerline Cross Bullish
2021-04-09 CELC MACD Bullish Signal Line Cross Bullish
2021-04-09 CELC Parabolic Rise Strength
2021-04-09 CELC Pocket Pivot Bullish Swing Setup
2021-04-09 CRDF Stochastic Reached Oversold Weakness
2021-04-09 CRDF Bollinger Band Squeeze Range Contraction
2021-04-09 CRDF Narrow Range Bar Range Contraction
2021-04-09 DCPH NR7 Range Contraction
2021-04-09 DCPH Narrow Range Bar Range Contraction
2021-04-09 DCPH 20 DMA Support Bullish
2021-04-09 IDYA Fell Below 50 DMA Bearish
2021-04-09 IDYA 180 Bearish Setup Bearish Swing Setup
2021-04-09 IDYA Stochastic Reached Oversold Weakness
2021-04-09 OLMA Narrow Range Bar Range Contraction
2021-04-09 OLMA NR7 Range Contraction
2021-04-09 POAI Pocket Pivot Bullish Swing Setup
2021-04-09 POAI Crossed Above 50 DMA Bullish
2021-04-09 SBTX Stochastic Buy Signal Bullish
2021-04-09 TCON Fell Below 20 DMA Bearish

Recent News for Targeted Therapy Stocks

Date Stock Title
Apr 12 CRDF Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC
Apr 12 POAI 51 Biggest Movers From Friday
Apr 12 CELC 51 Biggest Movers From Friday
Apr 12 MRTX BeiGene's tislelizumab combo study shows antitumor activity in solid tumors
Apr 10 MRTX Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
Apr 10 MRTX The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Apr 10 CRDF Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC
Apr 10 CRDF Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
Apr 10 CELC 15 Best Stocks in the Past Week: Square, Roku, Pinterest
Apr 9 CELC Mid-Afternoon Market Update: Dow Surges Over 100 Points; Provention Bio Shares Plunge
Apr 9 MRTX Seeking Alpha Catalyst Watch
Apr 9 CALA Calithera Biosciences (CALA) Investor Presentation - Slideshow
Apr 9 CELC How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A Breakout
Apr 9 CELC Celcuity surges 48% following licensing deal with Pfizer
Apr 9 CELC What's Going On With CELC Stock And PRVB Stock Today?
Apr 9 TPTX Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
Apr 9 CELC The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Apr 9 CELC Celcuity Stock Moves Higher After Licensing Pact With Pfizer For Gedatolisib In Breast Cancer
Apr 8 CELC Celcuity, Pfizer ink licensing agreement up to $340M for breast cancer treatment gedatolisib
Apr 8 CELC Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update